Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Executive Summary
Bristol's surprising purchase diversifies its portfolio beyond Opdivo, while stopping Celgene's ongoing stock price declines after several setbacks. While Bristol execs downplayed the mid-term risk of generics for Celgene's blockbuster Revlimid, they highlighted near- and long-term growth drivers.
You may also be interested in...
Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight
Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.
BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.
BMS ‘Slow-Rolled’ Approval of Liso-Cel, Investors Claim, Citing Timeline Of Other CAR-T Therapies
Two complaints allege BMS deliberately delayed approval of non-Hodgkins lymphoma treatment to avoid $6.4bn contingency payment. Former FDA reviewer is expert for plaintiffs in securities class action arguing that similar cell therapies Yescarta and Kymriah were approved twice as fast.